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Peptide Nanoparticles
Structural Determinants of the Stability of Enzyme-Responsive
Polyion Complex Nanoparticles Targeting Pseudomonas
aeruginosa’s Elastase
Ignacio Insua,[a, b] Marion Petit,[a] Lewis D. Blackman,[c] Robert Keogh,[c] Anaı¨s Pitto-Barry,[c, e]
Rachel K. O’Reilly,[c] Anna F. A. Peacock,[a] Anne Marie Krachler,[b, d] and Francisco Fernandez-
Trillo*[a, b]
Abstract: Here, we report how the stability of polyion
complex (PIC) particles containing Pseudomonas aeruginosa’s
elastase (LasB) degradable peptides and antimicrobial poly
(ethylene imine) is significantly improved by careful design of
the peptide component. Three LasB-degradable peptides are
reported herein, all of them carrying the LasB-degradable
sequenceGLA and for which the number of anionic amino
acids and cysteine units per peptide were systematically
varied. Our results suggest that while net charge and
potential to cross-link via disulfide bond formation do not
have a predictable effect on the ability of LasB to degrade
these peptides, a significant effect of these two parameters
on particle preparation and stability is observed. A range of
techniques has been used to characterize these new materials
and demonstrates that increasing the charge and cross-
linking potential of the peptides results in PIC particles with
better stability in physiological conditions and upon storage.
These results highlight the importance of molecular design
for the preparation of PIC particles and should underpin the
future development of these materials for responsive drug
delivery.
Introduction
Polyion complex (PIC) (nano)particles, also known as polyelec-
trolyte complexes (PECs)[1] or interpolyelectrolyte complexes
(IPECs),[2] are soft colloids obtained from the self-assembly of
oppositely charged polyelectrolytes in solution.[3] These nano-
materials are attractive vehicles for the delivery of charged
drugs such as antineoplastics,[4–7] antimicrobials[8–14] and nucleic
acids,[15] which can be complexed with oppositely charged
polymers to form PIC (nano)particles that reduce the toxicity
and/or control the activity of these drugs. Given the key role of
enzymes in many diseases and their remarkable specificity,[16]
PIC (nano)particles prepared from polyelectrolytes that degrade
in the presence of these enzymes have a great potential for
biomedical applications. This approach is particularly interesting
to tackle infections, since many pathogens secrete enzymes
(e.g. proteases) to overcome the host defenses.[17] By incorpo-
rating enzyme-responsive components into the PIC (nano)
particle, the release of the antimicrobial can be localized to the
surroundings of the pathogenic organism, leading to improved
therapeutic profiles.
With these principles in mind, we have recently reported
the preparation of enzyme-responsive PIC nanoparticles for the
targeted delivery of antimicrobial branched poly(ethylene
imine) (B-PEI), which was released upon exposure to Pseudomo-
nas aeruginosa’s elastase LasB.[18] To this end, anionic peptide
P1SH (Figure 1) was designed, that contained the amino acid
sequence glycine-leucine-alanine (GLA), which is hydrolyzed
by LasB. This sequence was inserted in between two glutamic
acids (E), responsible for the electrostatic interaction with B-PEI,
and two cysteines (C), to cross-link via disulfide formation once
the nanoparticle is formed. The reported PIC nanoparticles
showed excellent potential for the targeted delivery of B-PEI to
P. aeruginosa, being specifically degraded by the bacterial
elastase and displaying a LasB-specific activity against P.
aeruginosa. However, the overall antimicrobial activity of the
particles was low, with only 20% of the activity of free B-PEI
[a] Dr. I. Insua, M. Petit, Dr. A. F. A. Peacock, Dr. F. Fernandez-Trillo
School of Chemistry
University of Birmingham
Edgbaston, B15 2TT, UK
E-mail: f.fernandez-trillo@bham.ac.uk
[b] Dr. I. Insua, Dr. A. M. Krachler, Dr. F. Fernandez-Trillo
Institute of Microbiology and Infection – School of Biosciences
University of Birmingham
Edgbaston, B15 2TT, UK
[c] Dr. L. D. Blackman, R. Keogh, Dr. A. Pitto-Barry, Prof. R. K. O’Reilly
Department of Chemistry
University of Warwick
Coventry, CV4 7AL, UK
[d] Dr. A. M. Krachler
Current address: Department of Microbiology and Molecular Genetics,
University of Texas Health Science Center, Houston (TX), USA
[e] Dr. A. Pitto-Barry
Current address: School of Chemistry and Biosciences, University of Bradford,
Bradford BD71DP
Supporting information for this article is available on the WWW under
https://doi.org/10.1002/cnma.201800054
© 2018 The Authors. Published by Wiley-VCH Verlag GmbH & Co. KGaA.
This is an open access article under the terms of the Creative Commons
Attribution License, which permits use, distribution and reproduction in any
medium, provided the original work is properly cited.
1ChemNanoMat 2018, 4, 1 –9  2018 The Authors. Published by Wiley-VCH Verlag GmbH & Co. KGaA
Full PaperDOI: 10.1002/cnma.201800054
Wiley VCH Mittwoch, 16.05.2018
1899 / 109851 [S. 1/9] 1
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
recovered in the presence of P. aeruginosa. Due to the low
multivalency of peptide P1SH, only a small range of formulations
resulted in the formation of stable PIC nanoparticles, thus
compromising optimization of the delivery system.
In this article, we present our efforts to improve the stability
of these LasB-responsive PIC particles by optimizing the
structure of the peptide component. Three new LasB-respon-
sive peptides were prepared with increasing number of anionic
residues and cross-linking groups (Figure 1, P2SH-P4SH). The
hydrolysis of peptides P2SH-P4SH by LasB was evaluated and
compared to that caused by a model human elastase. While the
extent and specificity of hydrolysis was influenced by their
amino acid sequence, no clear correlation between multi-
valency and susceptibility to LasB was observed. When mixed
with the antimicrobial B-PEI, all these peptides were able to
give PIC particles across a wide range of formulations.
Representative PIC particles were characterized using a range
of light scattering techniques, suggesting that no significant
structural differences could be observed between nanopar-
ticles. Finally, the stability of these nanoparticles under
simulated physiological conditions or under storage was also
evaluated. Overall, particles prepared with the new peptides
P2SH-P4SH showed better stability than those obtained from
P1SH, with increasing stability in simulated physiological con-
ditions as the multivalency of the peptides was increased.
Results and Discussion
Peptide Design and Synthesis
Based on the structure of LasB-responsive peptide P1SH (Ac-C-E-
GLA-E-C-OH), previously reported by our group,[18] two mod-
ifications were proposed to enhance the saline stability of the
resulting PIC nanoparticles: i) Additional glutamic acids were
introduced to increase the number of anionic residues (Fig-
ure 1, P2SH and P3SH), potentially leading to a stronger affinity
for antimicrobial B-PEI; and ii) the incorporation of a third
cysteine (Figure 1, P4SH), which is expected to increase the
cross-linking density via disulfide formation once the PIC
nanoparticles are formed. Both charge density and cross-linking
density have been reported as factors contributing to the
stability of this type of nanoparticles.[3] Overall, the peptides
prepared included either two additional glutamic acids (P2SH),
four additional glutamic acids (P3SH), or four additional glutamic
acids and an extra cysteine (P4SH) compared to the parent
peptide P1SH. All peptides were synthesized by solid-phase
chemistry in good to excellent yields and high purity without
any chromatographic purification (see SI: Figures S1–S3† for
experimental details and characterization).
Enzymatic Degradation of Peptides
Next, the degradation of peptides P1SH–P4SH by P. aeruginosa’s
elastase (LasB) was evaluated. This experiment involved
quantification of the number of primary amines formed as a
result of peptide hydrolysis, using the fluorescent reporter
fluorescamine.[19] P. aeruginosa’s LasB hydrolyses peptides
containing the GLA sequence between the glycine and
leucine residues.[20] In these experiments, the fluorescent
intensity of all fluorescamine adducts (Figure S4) was compared
to that observed in the presence of H2N-LAE-OH (P5). P5’s
sequence should be formed following LasB-mediated hydrolysis
of the GLAE sequence, present in all the peptides reported.
Thus, 100% hydrolysis was assigned to the fluorescent intensity
of the fluorescamine adduct of P5 and all other intensities
reported as a percentage of this one (Figure 2). The degrada-
tion of peptides P1SH–P4SH in the presence of Human Leukocyte
Elastase (HLE), a protease released by white blood cells during
P. aeruginosa infections,[21] was also evaluated. This comparison
allowed us to assess if these peptides were selectively hydro-
lyzed by the bacterial elastase over a relevant human enzyme.
All peptides were hydrolyzed by LasB, in agreement with
our previous work that demonstrated that the addition of extra
amino acids around the GLA tripeptide did not seriously
compromise the activity of LasB.[18] We anticipated that
increasing the number of glutamic acids could have a
detrimental effect on the activity of LasB, due to the potential
sequestration of Ca2+ by carboxylic acids. Ca2+ is a LasB
cofactor and polycarboxylated compounds, in our case ethyl-
enediaminetetraacetic acid (EDTA), are commonly used to
quench the activity of the enzyme. However, no obvious trend
was observed for our peptides. P1SH, P3SH and P4SH displayed
Figure 1. Structures of the LasB-degradable peptides evaluated in this work
and their self-assembly with branched poly(ethylene imine) (B-PEI) to form
antimicrobial PIC particles.
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the highest susceptibility to LasB hydrolysis, with no statistical
difference between them (Figure 2). Interestingly, P2SH was the
least active of the peptides tested, despite having an
intermediate number of glutamic acid residues. The potential of
these peptides to adopt different conformations in solution
that could explain this difference in activity was evaluated using
circular dichroism (CD). However, CD suggested that all
peptides had a random/extended conformation in solution
without any significant difference across the collection (Fig-
ure S5A).[22] Finally, introducing an additional cysteine did not
have a big effect on the activity of LasB, with the number of
amines obtained from the hydrolysis of P4SH only 5% smaller
than those obtained from P3SH. However, this extra cysteine
had a significant effect on the specificity of the peptide with
P4SH being the only peptide significantly degraded by HLE (ca.
50% of the hydrolysis observed with LasB, Figure 2). This loss of
specificity is in agreement with the ability of HLE to cleave at
cysteine residues,[23,24] while LasB’s activity is moderately
inhibited by thiols and cysteine residues.[25–27]
Self-assembly and Characterization of PIC Particles
Having established that all peptides were hydrolyzed by LasB,
we then explored their suitability for the preparation of B-PEI
containing PIC nanoparticles. These nanoparticles were pre-
pared by mixing peptides P1SH–P4SH with B-PEI in aqueous
medium at physiological pH as previously reported for P1SH.
[18]
The colloidal stability of PIC particles is highly dependent on
their charge ratio (i. e. the relative number of positive and
negative charges mixed in the formulation). Therefore, several
formulations were explored for each peptide, where the relative
number of cationic amines in B-PEI versus anionic carboxylic
acids in peptides P1SH–P4SH (N :COOH ratio) was systematically
varied (Figure 3, Table S1). From their z-potentials, formulations
of these LasB-responsive peptides could be split into 3 groups:
a) Formulations resulting in the formation of cationic nano-
particles: While this was the case for all of the formulations
made from P1SH (Figure 3, top), only those formulations with
the smallest amounts of P2SH–P4SH peptides resulted in particles
with a positively charged corona (Figure 3, 0.4 and 0.3 N :COOH
ratios). b) Formulations that yielded negatively charged nano-
particles: We had previously reported that P1SH was unable to
form negatively charged particles (Figure 3, top),[18] possibly
because of its small size and multivalency. We were therefore
very pleased to see that increasing the multivalency for P2SH–
P4SH, resulted in particles with a negatively charged corona for
a broad range of formulations (Figure 3). This was particularly
the case for P3SH and P4SH, the two peptides with the highest
multivalency of the ones reported, which yielded negatively
charged particles for formulations with N :COOH ratios 0.6.
c) A region where no PIC nanoparticles formed in agreement
with the mechanism of nucleation for this type of
supramolecular aggregates.[2,3,28] When mixed, polyelectrolytes
will interact to form a neutral core made of a stoichiometric
mixture of oppositely charged polyelectrolytes, surrounded by
a corona of whichever polyion is present in excess. Neutral
complexes that lack a charged stabilizing corona will not be
colloidally stable and flocculation of particles will occur. While
this phenomenon was observed at 1 :1 N :COOH ratios or above
for P1SH,
[18] unstable particles were formed at a 1 :0.5 N :COOH
ratio for all the new peptides. Interestingly, P2SH showed the
smallest range of formulation that yielded colloidally stable
particles (Figure 3), suggesting again that this peptide may
adopt a different conformation in solution. The deviation from
the theoretical neutral point at N :COOH=1 :1 towards B-PEI-
rich mixtures had been previously described for other B-PEI-
containing PIC nanoparticles,[29] and it is likely a result of the
incomplete protonation of all amines in B-PEI due to Coulombic
interactions between neighboring ammonium groups.[30] Sim-
ilarly, since peptides with higher multivalencies should have
stronger affinities for B-PEI, the exchange of the peptides with
higher multivalency (i. e. P3SH and P4SH) between PIC nano-
particles and the solution should be slower than for the smaller
peptides, thus trapping colloidally stable intermediates even at
N :COOH ratios that should favor the formation of neutral PIC
nanoparticles. Additionally, P3SH and P4SH showed no significant
difference in the size or charge of any of the resulting PIC
nanoparticles (Figure 3), suggesting that multivalency is the
predominant factor that governs the self-assembly of this
collection of peptides. Regardless of the peptide used, no PIC
nanoparticles could be detected at a 1 :0.2 N :COOH ratio,
probably as a result of the incomplete complexation of
polyelectrolytes at this low concentration of peptide. The
polydispersity indices (PDIs) of all PIC nanoparticles ranged
between 0.01–0.06 with the exception of the formulations
prepared at a 1 :0.3 N :COOH ratio, which displayed significantly
higher PDI values of up to 0.17 (Table S1). It was clear from
dynamic light scattering (DLS) studies that formulations with
Figure 2. Relative amine content in samples of LasB responsive anionic
peptides evaluated in this work. Relative amine content was calculated from
fluorescamine conjugates formed following incubation with enzymes for 4
hours and normalized to the fluorescence observed with a model
degradation peptide (P5, H2N-LA-E-OH) (Figure S4). n=3, mean values
standard deviation. One-way ANOVA, followed by Tukey’s test (CI=95%,)
was used to test for significance. Statistical significance was determined ‘n/
s’=not significant, *** p<0.001.
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lower peptide contents led to broader size distributions,
although this phenomenon was less pronounced as the net
charge of the peptide increased (Figure S6).
Size-wise, P2SH–P4SH formulations showed a smaller varia-
bility in size than those reported for P1SH (Figure 3). Particles
with larger hydrodynamic diameters (DH) were obtained for
P2SH (ca. 300–400 nm) than for P3SH and P4SH (ca. 100–300 nm),
regardless of the N :COOH ratio tested (Figure 3). Nanoparticles
of smaller size for these two peptides could be the result of
their higher multivalency (7 COOH groups for P3SH and P4SH
versus 5 for P2SH and 3 for P1SH), which would result in more
strongly and tightly bound polyelectrolyte networks within
these nanoparticles. For all peptides, formulations prepared at a
1 :0.3 N :COOH ratio gave the smallest PIC nanoparticles, with
an average DH of ca. 110 nm and z-potential of +19 mV – in
agreement with the values previously found for P1SH at this
N :COOH ratio.[18]
Structural Characterization of PIC Particles
To further understand the impact that the multivalency and
cross-linking units of peptides P1SH–P4SH have on the structure
of the PIC nanoparticles formed, these materials were charac-
terized by Static Light Scattering (SLS). Multi-angle SLS analysis
of nanomaterials allows the calculation of their radius of
gyration (Rg) by deconvolution of the Zimm equation
(Eq. 1);[31,32] where K is a constant containing the optical
parameters, c is the concentration of the sample, Rq the
Rayleigh ratio of the particles at a given scattering angle (q), q
is the scattering wave vector and MwPIC is the average
molecular weight of the nanoparticles. Thus, the ratio between
gyration and hydrodynamic radii (i. e. Rg/RH), calculated by SLS
and DLS respectively, provides valuable information about the
internal structure and shape of nanomaterials.[31]
Kc
Rq
¼ Rg
2
3 MwPIC
 q2 þ 1
MwPIC
ð1Þ
PIC nanoparticles prepared from all four peptides at a
1 :0.3 N :COOH ratio were selected for SLS analysis, being the
most consistent formulation throughout the collection of
peptides studied. The scattering intensity from a suspension of
PIC nanoparticles was measured at different angles ranging
from 20 to 1008, and their DLS profiles were simultaneously
recorded. Unfortunately, non-linear Zimm plots were obtained
for all PIC particle samples with deviations at low angles, which
made impossible the accurate measurement of MwPIC and Rg
(Figure S7). Since larger particles have higher scattering con-
tributions at low angles,[32] we considered that this non-linearity
Figure 3. Hydrodynamic diameter (DH, left) and z-potential (right) of PIC nanoparticles prepared from peptides P1SH–P4SH at different N :COOH ratios. Each
value represents the mean size and charge of the only population fitted by the software for each sample  its standard deviation. Empty spaces indicate
formulations that did not form PIC particles. Further details can be found in Table S1. Results obtained directly after the assembly of the nanoparticles without
prior filtration. Data for P1SH reproduced from I. Insua, E. Liamas, Z. Zhang, A. F. Peacock, A. M. Krachler, F. Fernandez-Trillo, Polym Chem 2016, 7, 2684–2690 –
Published by The Royal Society of Chemistry.
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could be corrected by filtering the samples through mem-
branes with a pore size of 0.45 mm, and thus remove any
scatterers larger than the expected nanoparticles – which were
all smaller than the filter’s cut-off size according to our previous
DLS characterization (Figure 3). All filtered samples of PIC
nanoparticles displayed linear Zimm plots that allowed the
calculation of their Rg, which was then compared with the RH
obtained by DLS under the same conditions (Figure 4). The
average RH measured from filtered samples was 57.5 nm, which
is in agreement with the DH previously obtained from unfiltered
nanoparticles (ca. 110 nm), suggesting that the filtration did not
affect the main composition of PIC nanoparticles in the
samples.
Nanoparticles prepared from peptides P2SH–P4SH consis-
tently showed an Rg/RH value of 1.0, whereas those containing
the peptide P1SH presented a slight deviation towards Rg/RH >
1, which is characteristic of anisotropic nanomaterials.[31] This
difference can be explained from the tendency of the latter
nanoparticles to aggregate, as observed when their DH was
monitored over time (Figure S8): Whereas PIC nanoparticles
prepared from peptides P2SH–P4SH displayed the same size over
time, the DH of the nanoparticles made from P1SH increased by
50% after 10 days, which was the time that passed between the
preparation of these PIC nanoparticles and their SLS analysis.
Nevertheless, the Rg/RH values found for this collection of
nanoparticles are in agreement with those reported in the
literature for other PIC nanoparticles (1.0–1.6).[33,34] These Rg/RH
ratios, which are higher than the value expected for a solid
sphere (0.775),[31] have been rationalized by the high polydis-
persity of PIC nanoparticles and their tendency to aggregate in
some cases.[33,35] Both of these factors act as a bias towards
higher Rg/RH values, making the elucidation of the internal
structure of these nanomaterials extremely difficult.
In summary, the structural characterization of these nano-
particles by SLS and DLS indicates that all formulations have
very similar Rg and RH regardless of the peptide used, and
therefore no distinct structural features should be expected in
any of these complexes.
Stability under Physiological Conditions of PIC Particles
The electrostatic forces that keep PIC nanoparticles together
can be shielded by small electrolytes, leading to swelling and
ultimately breakdown of these nanoparticles.[36] Hence, the
integrity of PIC nanoparticles is often compromised by the
concentrations of salts present in biological fluids. This lack of
stability was the case for our previously reported nanoparticles,
for which only one of the formulations was stable under
simulated physiological conditions (Figure 5 and Figure S9,
P1SH, 0.3 N :COOH ratio). The tolerance to physiological con-
ditions of the new nanoparticles was evaluated by incubation
in the presence of 154 mM NaCl at 37 8C, and the change of DH
was monitored over four hours (Figure 5).
All PIC nanoparticles swelled when exposed to NaCl and
this swelling was inversely proportional to the peptides’ multi-
valency and the degree of cross-linking in the particle. As
predicted, increasing the multivalency in the peptide resulted
in tighter nanoparticles, that swelled less in the presence of
NaCl (Figure 5). For all peptides, nanoparticles made at a 1 :0.3
N :COOH ratio swelled the most, with particles prepared from
P2SH and P3SH becoming over 20 times bigger after 4 hours of
incubation (Figure 5A), a similar increase in size to that reported
for P1SH. Interestingly, those prepared from P4SH, which carries
an extra cysteine and should give higher cross-linking densities
at the same N :COOH ratio, were the least affected by this saline
medium, regardless of the formulation employed (Figure 5, ).
Overall, all the particles prepared with the new peptides
P2SH–P4SH showed better physiological stabilities than those
previously reported for trivalent P1SH (Figure 5, *),
[18] reinforc-
ing the correlation between peptide multivalency and PIC
nanoparticle stability (Figure 5 and Figure S9). Particles pre-
pared from the least multivalent peptide P2SH showed more
polydisperse aggregates after 2 and 3 hours and, for those
prepared at a 1 :1 N :COOH ratio, no particles could be detected
after 4 hours of incubation under these conditions (Figure 5E,
*). These results highlight the critical effect that multivalency
and cross-linking degree have on the salt tolerance of PIC
particles, as evidenced by their physiological stability: P1SH<
P2SH<P3SH<P4SH.
Stability Upon Freeze-drying
Finally, we evaluated if the increase in stability observed under
physiological conditions for the nanoparticles formed with the
new peptides P2SH–P4SH could be correlated to an increased
stability upon storage. Nanoparticles prepared at a 1 :0.3
N :COOH ratio were selected for this evaluation, being a
consistent formulation across all peptides evaluated. Also,
nanoparticles prepared at this N :COOH ratio have the least
amount of peptide and while stable, swelled more upon
incubation in physiological conditions. This swelling may
Figure 4. Partial Zimm plots obtained by SLS of filtered PIC particles
prepared from peptides P1SH–P4SH at a 1 : 0.3 N :COOH ratio. The inset
indicates the gyration (Rg) and hydrodynamic (RH) radii simultaneously
calculated by SLS and DLS, respectively.
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indicate that the cohesive forces in the core of these nano-
particles are weak enough to accommodate the presence of
competing counterions, or a higher tendency to aggregate,
making it an ideal formulation to test stability. To this end,
freshly prepared nanoparticles at this N :COOH ratio were
allowed to stand in a dark, cool and dry place, and their size
monitored over time (Figure S8). As described before, no
change in size was observed for any the nanoparticles prepared
with the new peptides P2SH–P4SH, even after 10 days of storage.
This was not the case for the nanoparticles prepared with P1SH
which quickly increased in size.
Nanoparticles prepared from P3SH at a 0.3 N :COOH ratio,
which showed excellent stability in solution, were then selected
as a representative example to evaluate the potential of these
formulations to be stored as a powder. Therefore, freshly
prepared nanoparticles from P3SH at a 0.3 N :COOH ratio were
freeze-dried overnight to yield a white powder. Approximately
1.32 mg of powder were recovered for all 3 samples prepared
(standard deviation 0.042), in close agreement with the 1.47 mg
expected taking into account the amount of peptide and B-PEI
used, and how much solid content was in the buffer used to
prepare the nanoparticle suspension. This powder was then
reconstituted in deionized water to give the original volume
(1 mL). Samples were then gently resuspended on a roller for
30 mins and characterized via DLS and z-potential. A small
increase in size was observed following resuspension (Fig-
ure 6A, *) in agreement with the small shift in the autocorre-
lation curve (Figure 6D), while no changes in the z-potential of
the particles were observed following resuspension on the
rollers (Figure 6B, *). A bigger effect was observed on the
number of counts, which decreased from 402.82.3 to 54.2
Figure 5. Relative change in size (DH/DH0) for PIC particles prepared from peptides P1SH–P4SH at representative N :COOH ratios under simulated physiological
conditions (37 8C, 154 mM NaCl, pH 7.4) (A 1 :0.3 [N :COOH] ratio, B 1 :0.4 [N :COOH] ratio, C 1 :0.6 [N :COOH] ratio, D 1 : 0.8 [N :COOH] ratio, E 1 :1 [N :COOH]
ratio and F 2 :1 [N :COOH] ratio). Particle size (DH) was normalized to that of the PIC particles in the absence of NaCl (0 hours, No change in size). n=3, mean
values standard deviation. Results obtained directly after the assembly of the nanoparticles without prior filtration. Data for P1SH reproduced from I. Insua, E.
Liamas, Z. Zhang, A. F. Peacock, A. M. Krachler, F. Fernandez-Trillo, Polym Chem 2016, 7, 2684–2690 – Published by The Royal Society of Chemistry.
Figure 6. Effect of freeze-drying and resuspension of the size (A), z-potential
(B) and number of counts (C) of nanoparticles prepared with P3SH at a
0.3 N :COOH ratio. Autocorrelation function curves for freshly prepared and
nanoparticles following resuspension on a roller for 30 mins (D) and
additional sonication for 30 sec (E) or 60 secs (F).
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1.2 (Figure 6C, *) suggesting that less particles were available
in suspension following reconstitution.
These samples were then sonicated for 30 or 60 seconds to
try to increase the number of nanoparticles in suspension.
While a small increase in the number of counts was observed
(Figure 6C,* and  for 30 and 60 secs respectively), sonication
had a detrimental effect on the nanoparticles and very noisy
autocorrelation function curves were obtained (Figure 6E and
F), which prevented accurate characterization of their size and
z-potential (Figure 6A and B).
Conclusions
Three new enzyme-responsive anionic peptides (P2SH–P4SH)
have been synthesized and their use in the preparation of PIC
nanoparticles containing the antimicrobial polymer B-PEI
reported. These peptides were designed to incorporate the
LasB-degradable sequence GLA, and increasing amounts of
glutamic acids for a stronger interaction with B-PEI (P2SH and
P3SH), and an additional cysteine (P4SH) to generate PIC nano-
particles with higher cross-linking density. The enzymatic
degradation of these peptides was assessed against bacterial
(LasB) and human (HLE) elastases and, while all peptides were
degraded by the bacterial elastase, no direct correlation with
the multivalency of the peptides could be identified. All new
peptides formed PIC nanoparticles when incubated with B-PEI,
and a broad range of formulations could be accessed by
varying the ratio of polyelectrolytes (i. e. N :COOH ratio). Our
results show that these new peptides allow the preparation of
negatively charged nanoparticles, not previously accessible
using the less multivalent peptide P1SH, previously reported by
our group.[18] More importantly, the stability of the new nano-
particles under simulated physiological conditions increased
with increasing multivalency and cross-linking degree of the
peptides (i. e. P2SH<P3SH<P4SH) and displayed higher saline
stability than those prepared using P1SH. The structural analysis
of these peptides and their resulting PIC nanoparticles by CD
and SLS, respectively, suggests that there are no differences in
conformation or architecture across the whole collection of
materials tested that could explain these differences in
susceptibility against LasB and stability. Finally, the stability of
representative formulations upon storage was evaluated. Our
results demonstrate the importance of carefully optimizing
peptide sequence and multivalency in the design of peptide-
based PIC particles and we believe these new peptides and
formulations will underpin the future development of “smart”
delivery systems for antimicrobials. Our efforts to identify LasB-
responsive nanoparticles with optimized release and antimicro-
bial activity, as well as the application of these peptides for the
preparation of other delivery systems, will be reported in due
course.
Experimental Section
Materials
Enzymes (Pseudomonas aeruginosa Elastase (LasB): EC 3.4.24.26 and
Human Leucocyte Elastase (HLE): EC 3.4.21.37) were purchased
from Merck Millipore. Branched poly(ethylene imine) 25 kDa
average molecular weight (B-PEI) and 4-(2-hydroxyethyl)piperazine-
1-ethanesulfonic acid (HEPES) were bought from Sigma-Aldrich.
Fluorescamine and dimethylsulphoxide (DMSO) were purchased
from Acros OrganicsTM. Ethylenediaminetetraacetic acid (EDTA) was
purchased from Alfa Aesar. Nylon 0.45 mm syringe filters were
purchased from Camlab.
Instrumentation
Dynamic Light Scattering (DLS) and z-potential measurements
were carried out with a Zetasizer Nano ZSP (Malvern Instruments
Ltd.) stabilized at 37 8C. DLS was read at 1738 (backscattering) for
60 seconds in triplicate and z-potentials were averaged from 30
measurements at 140 V. DLS correlograms were processed with
Malvern’s General Purpose non-negative least squares algorithm,
and their DH values correspond to the mean size and standard
deviation of the only population found in their size-intensity plots.
A FLUOstar Omega (BMGLabtech Gmbh) microplate reader was
used to incubate and measure fluorescamine reactions. Static Light
Scattering (SLS) and simultaneous DLS data was collected using an
CGS-3 Compact Goniometer System (ALV Gmbh) stabilized at 20 8C
and operating at a wavelength of 633 nm against a toluene
standard.
Preparation of PIC Nanoparticles
For nanoparticles prepared at a 1 :0.3 N :COOH ratio (defined as the
ratio between amines in B-PEI and carboxylic acids in the peptides),
stock solutions of B-PEI (2.5 mM in amines) and peptide (P1SH–P4SH)
(0.75 mM in carboxylate groups) in 5 mM HEPES buffer at pH 7.4
were prepared. Then, both solutions were filtered and mixed in
equal volumes drop-wise under stirring. The reaction mixture was
stirred at room temperature for 24 hours open to air to allow thiol
oxidation. PIC nanoparticles prepared at different N :COOH ratios
were obtained by changing the concentration of peptide stock
solution and mixing with the 2.5 mM B-PEI stock following the
same protocol (Table S1). After 24 hours, samples were analyzed
directly by DLS and z-potential without prior filtration.
Enzymatic Degradation of Peptides – Fluorescamine Assay
Stock solutions of peptide (1 mM) or succinyl casein (0.5 mg/mL)
were prepared in 25 mM Na2B4O7 buffer at pH 8.0 with 10 mM
CaCl2 and 10% v/v DMSO. 125 mL of these substrate solutions were
added to a 96-well black-walled microplate and mixed with 125 mL
of the same buffer without DMSO, containing 15 mg of enzyme
(LasB or HLE). Solutions of enzymes and substrates alone were
prepared as controls. Every sample was prepared in triplicate. The
microplate was incubated at 37 8C for 4 hours under orbital
shaking. After 4 hours, 50 mL of 0.1 M EDTA in water at pH 8.0 were
added to each well to quench all enzymatic activity. Then, each
sample was mixed in a 1 :1 volume ratio with a 1 mM solution of
fluorescamine[19] in methanol. The microplate was incubated at
37 8C under orbital shaking for 30 minutes. After this time,
fluorescence was measured exciting at 355 nm and reading the
emission at 46010 nm.
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Stability of PIC Nanoparticles in Simulated Physiological
Conditions
182 mL of a 1 M solution of NaCl in water was added to a sample of
PIC nanoparticles (1 mL), prepared as described above. This mixture
was then incubated at 37 8C to obtain physiological osmotic
pressure and temperature. Every hour, the sample was analyzed by
DLS as described above.
Freeze-drying and Resuspension of PIC Nanoparticles
A sample (1 mL) of freshly made PIC nanoparticles from P3SH and B-
PEI at a 1 :0.3 N :COOH ratio was frozen inside a tared 2 mL-
scintillation vial, to be then left overnight under vacuum at 80 8C.
A white solid was thus obtained, which was weighed by difference
inside the tared vial. Then, 1 mL of deionized water was added to
the vial and the mixture was gently and simultaneously rocked and
rolled for 30 min. After this time, the sample was characterized by
DLS and z-potential as indicated above. Replicates of this freeze-
dried and reconstituted sample were further processed by
immersion in an ultrasonic bath at room temperature for 30 and
60 sec, and characterized likewise. For the measurement of light
scattering intensity by DLS (i. e. counts, Figure 6C), the attenuator
value of the instrument was kept constant across all measure-
ments.
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PIC-a-boo! A series of anionic
peptides degradable by a bacterial
protease were incubated with a
cationic polymer, and the effect of
peptide multivalency on the structure
and stability of the resulting self-
assembled polyion complex (PIC)
nanoparticles was investigated.
Changes in the charge (i. e., number of
glutamic acids) and cross-linking (i. e.,
cysteine content) of the peptides
gave access to PIC nanoparticles with
remarkably improved saline stability
and good tolerance to dry storage
without any apparent effect on their
internal structure.
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1. Materials 
N-Fmoc-protected L-amino acids were purchased from Merck Millipore. N,N-dimethylformamide (DMF), 
piperidine 20% v/v in DMF and acetic anhydride were purchased from Sigma-Aldrich®. H-L-Cys(Trt)-
2-chlorotrityl resin (0.49 mmol/g) was bought from AGTC Bio Products Ltd. N,N-diisopropylethylamine 
(DIPEA), triisopropylsilane (TIPS), 1,2-ethanedithiol (EDT) and trifluoroacetic acid (TFA) were bought 
from Alfa Aesar®. N,N,N',N'-tetramethyl-O-(1H-benzotriazol-1-yl)uronium hexafluorophosphate 
(HBTU) was purchased from Carbosynth Ltd. All other chemicals were purchased from Fisher Scientific 
UK Ltd. and were used without further purification. 
2. Instrumentation 
NMR data was acquired on a Bruker Avance III operating at 400 MHz and fitted with a 5 mm DUL probe 
(1H/13C). MS spectra were obtained on a Xevo® G2-XS ToF (Waters) from electrospray ionisation (ESI) 
and time-of-flight (TOF) measurement in positive ion mode. High-resolution MS data was calculated by 
comparison with leucine-enkephalin as internal standard. Reverse phase (RP) HPLC analysis was run 
through a Kinetex® C18-EVO column (Phenomenex®): 5 μm, 100 Å, 250x4.60 mm. A gradient from 3 
to 20% of (CH3CN + 0.05% TFA) in (H2O + 0.05% TFA) was used at 1 mL/min. The column was 
maintained at 35°C and UV-VIS detection was set at 210 nm. Circular dichroism spectra were recorded 
in 1 mm path length quartz cuvettes on a Jasco J-715 spectropolarimeter. The observed ellipticity in 
millidegrees was converted into mean residue ellipticity and it is reported in units of degree⋅dmol-
1⋅cm2⋅residue-1.[1] 
3. Peptide synthesis 
500 mg of H-L-Cys(Trt)-2-chlorotrityl resin (0.245 mmol) were swollen in 5 mL of DMF for 30 minutes. 
Then, solutions of Fmoc-L-amino acid (3 eq), HBTU (2.8 eq) and DIPEA (2.8 eq) in DMF were added 
to a final volume of 5 mL. The reaction mixture was rolled for 1 h at room temperature, after which a 
negative chloranil test[2] indicated the reaction had gone to completion. The N-terminal Fmoc protecting 
group was removed by washing the resin with 5 mL of piperidine 20% v/v in DMF during 10 minutes. A 
positive chloranil test confirmed the removal of the Fmoc group, and the previous steps were repeated 
to couple all amino acids in the sequence. Following the coupling of the last amino acid, the Fmoc group 
was removed and the terminal amine of the peptide was capped by reacting with 5 mL of acetic 
anhydride:DIPEA:DMF (1:1:3) for 1 h at room temperature. Then, the resin was thoroughly washed with 
DMF and diethyl ether, and the peptide was cleaved from the resin with 5 mL of a mixture containing 
TFA (80%), TIPS (8%) and EDT (12%) for 2 h. After this time, the solution was concentrated under 
argon and precipitated in chilled diethyl ether:hexane (1:4). Finally, the suspension was centrifuged and 
the pellets were washed twice with diethyl ether:hexane (1:4), dissolved in water and freeze-dried. 
Peptides that showed impurities by 1H-NMR (e.g. trityl protecting groups) were further purified by 
dissolving the material in 2 mL of a 10% TIPS solution in TFA and precipitating in chilled diethyl 
ether:hexane (1:4), to be then centrifuged and freeze-dried as explained above. Peptide purity was 
determined by HPLC. 
4. Peptide characterisation 
The synthesis and characterisation of peptides P1SH (Ac-CEGLAEC-OH) and P5 (H2N-LAE-OH) has 
been previously reported.[3] 
  
Electronic Supplementary Information (ESI) 
3 of 11 
 
P2SH, Ac-CEEGLAEEC-OH (154.8 mg, 62% yield) 1H-NMR (400 MHz, DMSO-d6): δ 0.84(dd, J=15.0, 
6.5 Hz, 6H, Hδ-Leu); 1.20(d, J=7.1 Hz, 3H, Hβ-Ala 1.35-1.47(m, 2H, Hβ-Leu); 1.50-1.63(m, 1H, Hγ-Leu); 
1.66-1.80(m, 4H, Hβ-Glu); 1.84-1.96(m, 4H, Hβ-Glu); 1.87(s, 3H, Ac); 2.16-2.31(m, 8H, Hγ-Glu); 2.36(t, 
J=8.5 Hz, 1H, SH); 2.45(t, J=8.6 Hz, 1H, SH); 2.62-2.89(m, 4H, Hβ-Cys); 3.70(ddd, J=56.8, 16.7, 5.7 
Hz, 2H, Hα-Gly); 4.20-4.41(m, 8H, Hα); 7.89(d, J=8.1 Hz, 1H, NHCO); 7.92(d, J=8.5 Hz, 1H, NHCO); 
7.95(d, J=7.7 Hz, 1H, NHCO); 7.98(d, J=7.7 Hz, 1H, NHCO); 8.11-8.22(m, 5H, NHCO); 12.20(br.s, 4H, 
COOH) ppm. 13C-NMR (400 MHz, DMSO-d6): δ 17.4(Cβ-Ala); 21.4(Hδ-Leu ); 22.3(Ac); 22.9(Hδ-Leu); 
23.9(Hγ-Leu); 25.2(Cβ-Cys); 25.9(Cβ-Cys); 26.7(Cβ-Cys); 27.2(Cβ-Glu); 29.7(Cγ-Glu); 29.8(Cγ-Glu); 
29.8(Cγ-Glu); 29.9(Cγ-Glu); 40.7(Cβ-Leu); 41.6(Cα-Gly); 48.0(Cα); 50.6(Cα); 51.4(Cα); 51.5(Cα); 
51.8(Cα); 52.0(Cα); 54.2(Cα); 55.0(Cα); 168.5(NHCO); 169.8(Ac); 170.2(NHCO); 170.9(NHCO); 
171.0(NHCO); 171.1(NHCO); 171.3(NHCO); 171.4(NHCO); 171.9(NHCO); 172.2(NHCO); 
174.0(COOH) ppm. MS (ESI-TOF, +eV): m/z 1024.4 [M+H]+; 531.7 [M+Ca]2+. HR-MS (ESI-TOF, +eV): 
m/z 1024.3603 (calculated for [M+H]+); 1024.3605 (found). Purity by HPLC = 92% (Rt = 24.2 min). 
 
Figure S1 Characterisation of peptide P2SH (Ac-C-EE-GLA-EE-C-OH). Top: 1H (left) and 13C (right) 
NMR spectra (400 MHz, DMSO-d6). Bottom: Mass spectrum (left) and RP-HPLC chromatogram (right). 
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P3SH, Ac-CEEEGLAEEEC-OH (152.5 mg, 72% yield) 1H-NMR (400 MHz, DMSO-d6): δ 0.84(dd, 
J=14.8, 6.4 Hz, 6H, Hδ-Leu); 1.19(d, J=7.0 Hz, 3H, Hβ-Ala); 1.36-1.47(m, 2H, Hβ-Leu); 1.50-1.63(m, 1H, 
Hγ-Leu); 1.67-1.81(m, 6H, Hβ-Glu); 1.84-1.95(m, 6H, Hβ-Glu); 1.87(s, 3H, Ac); 2.17-2.29(m, 12H, Hγ-
Glu); 2.34(t, J=8.5 Hz, 1H, SH); 2.44(t, J=8.6 Hz, 1H, SH); 2.62-2.89(m, 4H, Hβ-Cys); 3.70(ddd, J=75.2, 
16.7, 5.7 Hz, 2H, Hα-Gly); 4.19-4.42(m, 10H, Hα); 7.89-7.94(m, 4H, NHCO); 8.04(d, J=7.4 Hz, 1H, 
NHCO); 8.08(d, J=7.6 Hz, 1H, NHCO); 8.11-8.20(m, 5H, NHCO); 12.17(br.s, 5H, COOH) ppm. 13C-
NMR (400 MHz, DMSO-d6): δ 17.4(Cβ-Ala); 21.4(Hδ-Leu); 22.3(Ac); 22.8(Hδ-Leu); 23.9(Hγ-Leu); 
25.2(Cβ-Cys); 25.9(Cβ-Cys); 26.7(Cβ-Cys); 27.0(Cβ-Glu); 27.1(Cβ-Glu); 27.2(Cβ-Glu); 29.9 (Cγ-Glu); 
40.8(Cβ-Leu); 41.6(Cα-Gly); 48.0(Cα); 50.6(Cα); 51.5(Cα); 51.6(Cα); 51.7(Cα); 51.8(Cα); 51.9(Cα); 
54.2(Cα); 54.9(Cα); 168.5(NHCO); 169.7(Ac); 170.1(NHCO); 171.0(NHCO); 171.0(NHCO); 
171.2(NHCO); 171.4(NHCO); 171.4(NHCO); 171.9(NHCO); 172.3(NHCO); 174.0(COOH) ppm. MS 
(ESI-TOF, +eV): m/z 1282.4 [M+H]+; 668.7 [M+H+Na+CH3OH]2+; 660.7 [M+Ca]2+; 641.7 [M+2H]2+. HR-
MS (ESI-TOF, +eV): m/z 1282.4455 (calculated for [M+H]+); 1282.4452 (found). Purity by HPLC = 90% 
(Rt = 23.8 min). 
 
Figure S2 Characterisation of peptide P3SH (Ac-C-EEE-GLA-EEE-C-OH). Top: 1H (left) and 13C (right) 
NMR spectra (400 MHz, DMSO-d6). Bottom: Mass spectrum (left) and RP-HPLC chromatogram (right). 
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P4SH, Ac-CEECEGLAEEEC-OH (208.0 mg, 98% yield) 1H-NMR (400 MHz, DMSO-d6): δ 0.84(dd, 
J=14.5, 6.6 Hz, 6H, Hδ-Leu); 1.19(d, J=7.0 Hz, 3H, Hβ-Ala); 1.36-1.46(m, 2H, Hβ-Leu); 1.51-1.61(m, 1H, 
Hγ-Leu); 1.67-1.81(m, 6H, Hβ-Glu); 1.83-1.95(m, 6H, Hβ-Glu); 1.87(s, 3H, Ac); 2.17-2.31(m, 12H, Hγ-
Glu); 2.36(dt, J=8.5, 2.8 Hz, 2H, SH); 2.44(t, J=8.5 Hz, 1H, SH); 2.62-2.89(m, 6H, Hβ-Cys); 3.70(ddd, 
J=54.5, 16.7, 5.8 Hz, 2H, Hα-Gly); 4.19-4.42(m, 11H, Hα); 7.90-8.20(m, 12H, NHCO); 12.16(br.s, 5H, 
COOH) ppm. 13C-NMR (400 MHz, DMSO-d6): δ 17.4(Cβ-Ala); 21.4(Hδ-Leu); 22.3(Ac); 22.9(Hδ-Leu); 
23.9(Hγ-Leu); 25.2(Cβ-Cys); 25.9(Cβ-Cys); 26.8(Cβ-Cys); 27.0(Cβ-Glu); 27.1(Cβ-Glu); 27.1(Cβ-Glu); 
27.2(Cβ-Glu); 40.8(Cβ-Leu); 41.6(Cα-Gly); 48.0(Cα); 50.5(Cα); 51.5(Cα); 51.6(Cα); 51.7(Cα); 51.9(Cα); 
52.1(Cα); 54.2(Cα); 54.8(Cα); 54.9(Cα); 168.4(NHCO); 169.7(Ac); 170.1(NHCO); 171.0(NHCO); 
171.0(NHCO); 171.1(NHCO); 171.1(NHCO); 171.2(NHCO); 171.3(NHCO); 171.4(NHCO); 
171.9(NHCO); 172.2(NHCO); 174.0(COOH) ppm. MS (ESI-TOF, +eV): m/z 1407.4 [M+Na]+; 1385.5 
[M+H]+; 712.2 [M+Ca]2+; 704.2 [M+H+Na]2+; 693.2 [M+2H]2+. HR-MS (ESI-TOF, +eV): m/z 1385.4547 
(calculated for [M+H]+); 1385.4545 (found). Purity by HPLC = 91% (Rt = 26.6 min). 
 
Figure S3 Characterisation of peptide P4SH (Ac-C-EE-C-E-GLA-EEE-C-OH). Top: 1H (left) and 13C 
(right) NMR spectra (400 MHz, DMSO-d6). Bottom: Mass spectrum (left) and RP-HPLC chromatogram 
(right). 
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5. Enzymatic degradation of peptides 
In this experiment several controls have been performed to ensure that the observed increase in 
fluorescence is related to the elastase-mediated hydrolysis of the peptides. 
• Succinyl casein (SC) is a positive control for enzymatic activity. This protein is degraded by most 
proteases, and an increase in fluorescence for SC in the presence of elastases indicates that these 
enzymes are active. 
• All substrates (e.g. peptide, SC) have been incubated for 4 h under assay conditions in the absence 
of the elastases and the fluorescence observed is represented by black bars. This includes buffer 
alone (black bar now labelled control). 
• P5, a peptide with a sequence that matches the hydrolysis product of one of our previously reported 
peptides,[4] was incubated in the absence of elastase and the fluorescence obtained was associated 
to 100% hydrolysis. 
 
 
Figure S4 Emission intensity (λexc 355 nm, λem 460 nm) of fluorescamine conjugates for buffer and 
enzymes (controls), succinyl casein (SC, a control for enzymatic activity) in the absence and presence 
of enzymes, peptides P1-4SH in the absence and presence of enzymes, and the peptide H2N-LA-E-OH 
(P5, a control to normalise fluorescence intensity). All samples were incubated for 4 hours. n = 3, mean 
± SD. 
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6. Circular dichroism characterisation of peptides 
 
Figure S5 Top: Circular dichroism absorption spectra of peptides P1-P4SH (A), and comparison 
between the spectra of P3SH, B-PEI and PIC particles prepared from these two materials at a 1:0.3 
[N:COOH] ratio (B). Bottom: Dynode (HT) voltages recorded for the spectra above (C-D).  
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7. PIC particle characterisation 
Table S1 Hydrodynamic diameter (DH), polydispersity index (PDI) and ζ-potential of PIC particles 
prepared from peptides P2-4SH and B-PEI at different [N:COOH] ratios. SD indicates the standard 
deviation found for the only size or charge population fitted by the software. 
The size and charge of PIC nanoparticle formulations prepared from peptide P1SH has been previously 
reported.[3] a PDI values were calculated from the DH and SD obtained by General Purpose (Malvern 
Instruments Ltd.) deconvolution of DLS correlograms using the following formula: PDI = (SD/DH)2.[5] 
Peptide [N:COOH] ratio 
DH ± SD 
(nm) PDI 
a ζ-potential ± SD (mV) Notes 
P2SH 
1 : 2.0 371 ± 51 0.02 -9.6 ± 3.9 - 
1 : 1.5 329 ± 42 0.02 -10.0 ± 3.1 - 
1 : 1.0 293 ± 30 0.01 -9.1 ± 3.5 - 
1 : 0.8 - - - No particles found 
1 : 0.7 - - - No particles found 
1 : 0.6 - - - No particles found 
1 : 0.5 - - - No particles found 
1 : 0.4 419 ± 67 0.03 +11.7 ± 5.2 - 
1 : 0.3 91 ± 32 0.12 +19.1 ± 6.2 - 
1 : 0.2 - - - No particles found 
P3SH 
1 : 2.0 227 ± 50 0.05 -21.3 ± 6.3 - 
1 : 1.5 204 ± 51 0.06 -18.5 ± 6.4 - 
1 : 1.0 198 ± 47 0.06 -18.3 ± 6.7 - 
1 : 0.8 212 ± 44 0.04 -16.5 ± 6.0 - 
1 : 0.7 224 ± 45 0.04 -16.0 ± 6.8 - 
1 : 0.6 280 ± 55 0.04 -15.8 ± 4.8 - 
1 : 0.5 - - - No particles found 
1 : 0.4 240 ± 47 0.04 +13.9 ± 5.1 - 
1 : 0.3 103 ± 42 0.17 +21.3 ± 7.9 - 
1 : 0.2 - - - No particles found 
P4SH 
1 : 2.0 198 ± 45 0.05 -20.6 ± 6.1 - 
1 : 1.5 192 ± 43 0.05 -20.6 ± 7.2 - 
1 : 1.0 191 ± 41 0.05 -20.2 ± 5.8 - 
1 : 0.8 173 ± 36 0.04 -17.0 ± 7.4 - 
1 : 0.7 176 ± 39 0.05 -17.7 ± 7.2 - 
1 : 0.6 205 ± 39 0.04 -11.1 ± 7.5 - 
1 : 0.5 - - - No particles found 
1 : 0.4 225 ± 46 0.04 +15.2 ± 5.4 - 
1 : 0.3 143 ± 40 0.08 +17.7 ± 7.7 - 
1 : 0.2 - - - No particles found 
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Figure S6 Representative DLS size-intensity distributions of freshly prepared PIC nanoparticles 
containing peptides P1SH-P4SH at different N:COOH ratios.  
8. SLS characterisation of unfiltered PIC particles 
  
Figure S7 Partial Zimm plots obtained by SLS of unfiltered PIC particles prepared from peptides P1-
4SH at a 1:0.3 [N:COOH] ratio. 
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9. Shelf stability of PIC particles 
   
Figure S8 Relative change in size (DH / DH0) over time of PIC particles prepared at a 1:0.3 [N:COOH] 
ratio, stored in a dark, cool and dry place. The DH values calculated by DLS were normalised to that of 
freshly made PIC particles (day 1). 
10. Stability of the particles under physiological conditions 
 
Figure S9 Relative change in size (DH / DH0) for PIC particles prepared from peptides P1SH-P4SH at 
representative N:COOH ratios under simulated physiological conditions (37 °C, 154 mM NaCl, pH 7.4)). 
Particle size (DH) were normalised to that of the PIC particles in the absence of NaCl (0 hours, No 
change in size). n = 3, mean values ± standard deviation. Results obtained directly after the assembly 
of the nanoparticles without prior filtration. Data for P1SH reproduced from I. Insua, E. Liamas, Z. Zhang, 
A. F. Peacock, A. M. Krachler, F. Fernandez-Trillo, Polym Chem 2016, 7, 2684–2690 - Published by 
The Royal Society of Chemistry. 
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